The Discovery of GHK-Cu Copper Tripeptide: Key Milestones in Early Peptide Research
Last Updated: March 26, 2026 Prepared by: Palmetto Peptides Research Team
DISCLAIMER: All content on this page is provided for educational and scientific research purposes only. GHK-Cu is a research compound sold exclusively for laboratory, in vitro, and preclinical research use. It is not approved by the FDA for human consumption, therapeutic use, or veterinary application. Nothing here constitutes medical advice.
The Discovery of GHK-Cu Copper Tripeptide: Key Milestones in Early Peptide Research
This article is part of our comprehensive GHK-Cu Research Peptide Complete Guide.
GHK-Cu was first identified in 1973 by researcher Loren Pickart, who discovered it in human plasma albumin while studying why plasma from young individuals caused aging liver tissue to behave like younger tissue. What began as a single unexpected observation grew into more than five decades of published research, making GHK-Cu one of the most extensively characterized naturally occurring research peptides in molecular biology.
The history of GHK-Cu is a useful case study in how peptide research evolves. It began with a serendipitous biological observation, moved through structural characterization and mechanism studies, and expanded over decades into gene expression biology, lung research, and more. Understanding that history helps contextualize why the current literature looks the way it does and why certain mechanisms were investigated before others.
For researchers who want to see GHK-Cu's full current research profile rather than its history, the Palmetto Peptides Complete Guide to GHK-Cu covers the breadth of published literature in one place.
The 1973 Discovery: A Plasma Fraction That Rejuvenated Old Tissue
The story starts not with peptide chemistry but with a biological puzzle. In the early 1970s, Loren Pickart was studying why plasma from young, healthy individuals caused aged liver tissue to synthesize proteins more characteristic of younger tissue. When he and colleagues isolated the active fraction from human plasma albumin, they found a small molecule with a surprisingly powerful effect on cellular behavior.
The initial characterization of this substance was published in 1973 in Biochemical and Biophysical Research Communications. Pickart and Thaler identified the active fraction as a tripeptide that stimulated CO2 production and lipid synthesis in liver slices, promoted protein, RNA, and DNA production in cell culture, and enhanced growth in hepatoma cells while supporting survival in normal liver cells. The molecule was tentatively identified as having an amino acid sequence of glycyl-L-histidyl-L-lysine, though the structural confirmation came in subsequent years.
The original discovery was published as: Pickart L, Thaler MM. "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver." Nature New Biology. 1973;243(124):85-87.
The 1980s: Structural Confirmation and Copper Binding
The decade following the initial discovery brought several critical advances that defined GHK-Cu as we understand it today.
Confirming the Amino Acid Sequence and Copper Affinity
In 1980, Pickart and colleagues published a paper in Nature establishing that the growth-modulating tripeptide may function by facilitating copper uptake into cells. This paper, which became one of the most cited in GHK-Cu research, established the copper-binding activity that gives the molecule its characteristic properties and its full name.
The structural analysis revealed that GHK forms a stable complex with copper(II) ions through coordinated binding involving the histidine imidazole ring and the terminal amine groups. The affinity for copper was found to be comparable to that of albumin's copper transport sites, an important observation because albumin is the primary copper carrier in human plasma.
The 1980 Nature paper: Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. "Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells." Nature. 1980;288(5791):715-717.
Wound Healing Research Begins
Also in the 1980s, research groups began investigating GHK-Cu's effects in wound models. Downey, Larrabee, Voci, and Pickart published early work in 1985 demonstrating acceleration of wound healing using the glycyl-histidyl-lysine copper complex. This opened a new direction that would become one of the largest bodies of GHK-Cu research over the following decades.
The 1988 Maquart et al. study established that GHK-Cu stimulated collagen synthesis in fibroblast cultures at remarkably low concentrations, beginning at picomolar levels and peaking at 1 nanomolar. This foundational fibroblast study set the standard concentration ranges for subsequent in vitro work and confirmed that GHK-Cu's collagen effects were direct and cell-number-independent.
The 1990s: Expanding Tissue Research and Mechanism Work
The 1990s saw the research base for GHK-Cu expand considerably beyond the original liver and wound contexts.
Connective Tissue and Glycosaminoglycan Synthesis
Wegrowski, Maquart, and Borel published work in 1992 demonstrating that GHK-Cu stimulates sulfated glycosaminoglycan synthesis, extending the picture of its extracellular matrix effects beyond collagen alone. This included stimulation of chondroitin sulfate and support for the small proteoglycan decorin, which plays a role in organizing collagen fibril architecture.
Maquart's group also confirmed through in vivo rat wound studies that GHK-Cu increased collagen I and collagen III expression in experimental wounds, with effects persisting from day 3 through day 14. This in vivo confirmation of the earlier fibroblast findings strengthened the case for GHK-Cu as a functionally relevant wound repair signal.
MMP and Anti-Protease Research
Research in the 1990s also established that GHK-Cu modulates matrix metalloproteinases and their inhibitors. The observation that it increased expression of both MMPs and their inhibitors led to the characterization of GHK-Cu as a regulatory molecule for the balance between matrix synthesis and breakdown, rather than simply a collagen stimulant.
Importantly, this decade's research also established that the copper-bound form was specifically required for the wound healing effects. Studies showed that GHK alone, without copper, did not replicate the collagen remodeling effects seen with GHK-Cu, demonstrating that copper binding was functionally essential to the molecule's biological activity in these models.
The 2000s: Genomic Tools and Broader Tissue Discovery
The availability of high-throughput genomic analysis tools transformed GHK-Cu research in the early 2000s. For the first time, it became possible to examine the molecule's effects across thousands of genes simultaneously rather than studying individual pathways one at a time.
The Connectivity Map and Gene Expression Analysis
The Broad Institute's development of the Connectivity Map (cMap) database, which contains gene expression profiles of human cell lines treated with thousands of bioactive compounds, allowed Pickart and colleagues to characterize GHK-Cu's genomic influence at a previously impossible scale.
Work published in 2014 in BioMed Research International (Pickart, Vasquez-Soltero, and Margolina) used cMap data to demonstrate that GHK-Cu influences more than 4,000 human genes. The analysis showed that GHK could shift gene expression patterns across categories including antioxidant defense, DNA repair, tissue remodeling, and inflammation regulation. The authors described the pattern as a "resetting" toward gene expression states characteristic of younger or healthier tissue.
The COPD Study: A Multi-Institution Milestone
One of the most cited GHK-Cu studies in the literature was published in 2012 in Genome Medicine by Campbell and colleagues, involving researchers from Boston University, the University of Groningen, the University of British Columbia, and the University of Pennsylvania. This collaborative study identified 127 genes associated with emphysema severity in COPD patients and used the cMap to identify GHK as a compound capable of reversing the associated gene expression signature.
Critically, the computational prediction was then confirmed in vitro: lung fibroblasts from COPD patients, which had impaired ability to contract and remodel collagen, regained that capacity when treated with GHK at 10 nM. This study is considered among the strongest pieces of mechanistic evidence in the GHK-Cu literature because it connected computational gene profiling with functional in vitro confirmation.
Key Research Milestones Timeline
| Year | Milestone | Publication |
|---|---|---|
| 1973 | GHK-Cu isolated from human plasma albumin | Pickart and Thaler, Nature New Biology |
| 1980 | Copper-binding mechanism established | Pickart et al., Nature |
| 1985 | First wound healing acceleration data | Downey et al., Surgical Forum |
| 1988 | Fibroblast collagen synthesis study | Maquart et al., FEBS Letters |
| 1992 | Glycosaminoglycan synthesis effects documented | Wegrowski et al., Life Sciences |
| 1993 | In vivo collagen I and III stimulation confirmed in rats | Maquart et al., Journal of Clinical Investigation |
| 2008 | Comprehensive tissue remodeling review | Pickart, Journal of Biomaterials Science |
| 2012 | COPD gene expression reversal: multi-institution study | Campbell et al., Genome Medicine |
| 2014 | 4,000+ gene influence documented via cMap | Pickart et al., BioMed Research International |
| 2017 | Nervous system gene expression effects characterized | Pickart et al., Brain Sciences |
| 2018 | Updated review of regenerative and protective actions | Pickart and Margolina, IJMS |
| 2022 | Nrf2 pathway activation in cigarette smoke model | Zhang et al., Frontiers in Molecular Biosciences |
| 2025 | SIRT1 identified as direct binding target | Mao et al., Frontiers in Pharmacology |
Why the History Matters for Researchers Today
The research history of GHK-Cu is directly relevant to how researchers should interpret current findings. Several features of this history are worth highlighting.
First, the research base is genuinely old and deep. GHK-Cu is not a compound with a handful of recent studies. It has been studied continuously for over 50 years, with publications across multiple countries, research institutions, and scientific disciplines. This gives researchers confidence that the basic observations are reproducible.
Second, the progression from biological observation to structural characterization to genomic analysis reflects how the field's tools have evolved. The genomic findings from the 2000s and 2010s are not separate from the older wound healing and fibroblast work; they provide mechanistic context for why those earlier effects occurred.
Third, the endogenous nature of GHK-Cu, its presence in human plasma and its decline with age, is a consistent thread through all eras of the research. The biological relevance of this decline remains an open research question, but it has motivated much of the sustained scientific interest in the compound.
Related Product: GHK-Cu Research Peptide (Palmetto Peptides) | For Research Use Only
Frequently Asked Questions
Who discovered GHK-Cu and when?
GHK-Cu was first identified by Loren Pickart in 1973 while studying a fraction of human plasma albumin that caused old liver tissue to synthesize proteins characteristic of younger tissue. The active molecule was identified as the tripeptide glycyl-L-histidyl-L-lysine, and its copper-binding activity was established in subsequent years.
What was the original experiment that led to GHK-Cu's discovery?
Pickart's original discovery came from experiments adding plasma from young individuals to liver tissue from older individuals. The young plasma caused the older liver tissue to produce proteins more characteristic of younger tissue. This regenerative activity was ultimately traced to the tripeptide GHK.
When did researchers establish that copper binding was essential to GHK's activity?
Research through the 1980s and 1990s established that the copper-bound form was specifically required for wound healing and skin remodeling effects in laboratory models. Studies comparing GHK with and without copper showed that the unbound peptide did not replicate the collagen remodeling effects of GHK-Cu.
When did broader genomic research on GHK-Cu begin?
Genomic research into GHK-Cu's effects on gene expression began expanding in the early 2000s, with major contributions from work using the Broad Institute's Connectivity Map. A significant 2012 collaborative study identified 127 COPD-associated genes and found GHK could reverse the associated gene expression signature.
Is GHK-Cu naturally present in the human body?
Yes. GHK-Cu is found in human plasma, saliva, and urine. Plasma concentration is approximately 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60.
Peer-Reviewed Citations
-
Pickart L, Thaler MM. "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver." Nature New Biology. 1973;243(124):85-87.
-
Pickart L, Freedman JH, Loker WJ, et al. "Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells." Nature. 1980;288(5791):715-717.
-
Maquart FX, Pickart L, Laurent M, et al. "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." FEBS Letters. 1988;238(2):343-346.
-
Wegrowski Y, Maquart FX, Borel JP. "Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." Life Sciences. 1992;51(13):1049-1056.
-
Campbell JD, McDonough JE, Zeskind JE, et al. "A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK." Genome Medicine. 2012;4(8):67.
-
Pickart L, Vasquez-Soltero JM, Margolina A. "GHK and DNA: Resetting the Human Genome to Health." BioMed Research International. 2014;2014:151479.
-
Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987.
Legal Notice: GHK-Cu is sold by Palmetto Peptides strictly as a research compound for laboratory use only. It is not approved by the FDA for any medical application and is not intended for human or veterinary use.
Palmetto Peptides Research Team Last Updated: March 26, 2026